Efficacy – LYNPARZA® (olaparib)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Efficacy – LYNPARZA® (olaparib)
Cureus | Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
ASCO GI 2021: Results From the Phase 3 POLO Trial
Treatment landscape of metastatic pancreatic cancer - Cancer Treatment Reviews
Cancer Trial Results
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Olaparib may delay metastatic pancreatic cancer in patients
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer - The ASCO Post
Efficacy – LYNPARZA® (olaparib)
ASCO GI 2021: Results From the Phase 3 POLO Trial
FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter
ASCO GI 2021: Results From the Phase 3 POLO Trial
